Align Technology enters $250M accelerated stock repurchase agreement
06 Feb 2023
AcquisitionIPO
Tempe, Arizona-based Align agreed to repurchase $250 million of its common stock. It falls under its $1 billion stock repurchase agreement announced in May 2021. The company’s most recent buyback took place in October 2022 through a $200 million repurchase with Goldman Sachs.
In this agreement, two of the dental technology company’s executives personally agreed to buy significant amounts of common stock. President and CEO Joe Hogan intends to purchase $1 million. CFO and EVP of Global Finance John Morici plans to buy $200,000 in common stock.
Under the terms of the repurchase, Align initially received approximately 580,000 shares of common stock. The final number of shares depends on Align’s volume-weighted stock price during the term of the deal. Align expects to complete the transaction by April 26, 2023, funding it with cash on hand.
As of Dec. 31, 2022, Align had approximately 77.3 million shares outstanding and $1 billion in cash, equivalents and securities. Shares of ALGN ticked up 1.2% at $347.05 apiece as the market opened today.
“We’re pleased to announce this latest $250 million ASR, which reflects the strength of our balance sheet and cash flow generation, as well as management’s and the board’s continued confidence in our ability to capitalize on the large market opportunities in our target markets and trajectory for growth,” Morici said. “Returning capital to our shareholders through stock repurchase programs while simultaneously investing in our strategic growth drivers, is consistent with our capital allocation strategy and commitment to increasing shareholder value.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.